These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
214 related articles for article (PubMed ID: 21220498)
1. MEK/ERK inhibitor U0126 increases the radiosensitivity of rhabdomyosarcoma cells in vitro and in vivo by downregulating growth and DNA repair signals. Marampon F; Gravina GL; Di Rocco A; Bonfili P; Di Staso M; Fardella C; Polidoro L; Ciccarelli C; Festuccia C; Popov VM; Pestell RG; Tombolini V; Zani BM Mol Cancer Ther; 2011 Jan; 10(1):159-68. PubMed ID: 21220498 [TBL] [Abstract][Full Text] [Related]
2. MEK/ERK inhibitor U0126 affects in vitro and in vivo growth of embryonal rhabdomyosarcoma. Marampon F; Bossi G; Ciccarelli C; Di Rocco A; Sacchi A; Pestell RG; Zani BM Mol Cancer Ther; 2009 Mar; 8(3):543-51. PubMed ID: 19258428 [TBL] [Abstract][Full Text] [Related]
3. Key role of MEK/ERK pathway in sustaining tumorigenicity and in vitro radioresistance of embryonal rhabdomyosarcoma stem-like cell population. Ciccarelli C; Vulcano F; Milazzo L; Gravina GL; Marampon F; Macioce G; Giampaolo A; Tombolini V; Di Paolo V; Hassan HJ; Zani BM Mol Cancer; 2016 Feb; 15():16. PubMed ID: 26897742 [TBL] [Abstract][Full Text] [Related]
4. p21WAF1 expression induced by MEK/ERK pathway activation or inhibition correlates with growth arrest, myogenic differentiation and onco-phenotype reversal in rhabdomyosarcoma cells. Ciccarelli C; Marampon F; Scoglio A; Mauro A; Giacinti C; De Cesaris P; Zani BM Mol Cancer; 2005 Dec; 4():41. PubMed ID: 16351709 [TBL] [Abstract][Full Text] [Related]
5. Down-regulation of c-Myc following MEK/ERK inhibition halts the expression of malignant phenotype in rhabdomyosarcoma and in non muscle-derived human tumors. Marampon F; Ciccarelli C; Zani BM Mol Cancer; 2006 Aug; 5():31. PubMed ID: 16899113 [TBL] [Abstract][Full Text] [Related]
6. Close correlation between MEK/ERK and Aurora-B signaling pathways in sustaining tumorigenic potential and radioresistance of gynecological cancer cell lines. Marampon F; Gravina GL; Popov VM; Scarsella L; Festuccia C; La Verghetta ME; Parente S; Cerasani M; Bruera G; Ficorella C; Ricevuto E; Tombolini V; Di Cesare E; Zani BM Int J Oncol; 2014 Jan; 44(1):285-94. PubMed ID: 24189697 [TBL] [Abstract][Full Text] [Related]
7. Hypoxia sustains glioblastoma radioresistance through ERKs/DNA-PKcs/HIF-1α functional interplay. Marampon F; Gravina GL; Zani BM; Popov VM; Fratticci A; Cerasani M; Di Genova D; Mancini M; Ciccarelli C; Ficorella C; Di Cesare E; Festuccia C Int J Oncol; 2014 Jun; 44(6):2121-31. PubMed ID: 24676782 [TBL] [Abstract][Full Text] [Related]
8. MEK inhibition of pancreatic carcinoma cells by U0126 and its effect in combination with sulindac. Yip-Schneider MT; Schmidt CM Pancreas; 2003 Nov; 27(4):337-44. PubMed ID: 14576498 [TBL] [Abstract][Full Text] [Related]
9. Importance of MEK-1/-2 signaling in monocytic and granulocytic differentiation of myeloid cell lines. Miranda MB; McGuire TF; Johnson DE Leukemia; 2002 Apr; 16(4):683-92. PubMed ID: 11960350 [TBL] [Abstract][Full Text] [Related]
10. Effect of MAPK Inhibition on the Differentiation of a Rhabdomyosarcoma Cell Line Combined With CRISPR/Cas9 Technology: An In Vitro Model of Human Muscle Diseases. De Luna N; Suarez-Calvet X; Garicano M; Fernandez-Simon E; Rojas-García R; Diaz-Manera J; Querol L; Illa I; Gallardo E J Neuropathol Exp Neurol; 2018 Oct; 77(10):964-972. PubMed ID: 30184235 [TBL] [Abstract][Full Text] [Related]
11. Mitogen-activated protein/extracellular signal-regulated kinase kinase (MEK) inhibitors restore anoikis sensitivity in human breast cancer cell lines with a constitutively activated extracellular-regulated kinase (ERK) pathway. Fukazawa H; Noguchi K; Murakami Y; Uehara Y Mol Cancer Ther; 2002 Mar; 1(5):303-9. PubMed ID: 12489846 [TBL] [Abstract][Full Text] [Related]
12. Novel combination of cyclooxygenase-2 and MEK inhibitors in human hepatocellular carcinoma provides a synergistic increase in apoptosis. Schmidt CM; Wang Y; Wiesenauer C J Gastrointest Surg; 2003 Dec; 7(8):1024-33. PubMed ID: 14675712 [TBL] [Abstract][Full Text] [Related]
13. Resistance to mitogen-activated protein kinase kinase (MEK) inhibitors correlates with up-regulation of the MEK/extracellular signal-regulated kinase pathway in hepatocellular carcinoma cells. Yip-Schneider MT; Klein PJ; Wentz SC; Zeni A; Menze A; Schmidt CM J Pharmacol Exp Ther; 2009 Jun; 329(3):1063-70. PubMed ID: 19258520 [TBL] [Abstract][Full Text] [Related]
14. Differential sensitivity of chemoresistant neuroblastoma subtypes to MAPK-targeted treatment correlates with ERK, p53 expression, and signaling response to U0126. Eppstein AC; Sandoval JA; Klein PJ; Woodruff HA; Grosfeld JL; Hickey RJ; Malkas LH; Schmidt CM J Pediatr Surg; 2006 Jan; 41(1):252-9. PubMed ID: 16410143 [TBL] [Abstract][Full Text] [Related]
15. DNMT3B in vitro knocking-down is able to reverse embryonal rhabdomyosarcoma cell phenotype through inhibition of proliferation and induction of myogenic differentiation. Megiorni F; Camero S; Ceccarelli S; McDowell HP; Mannarino O; Marampon F; Pizer B; Shukla R; Pizzuti A; Marchese C; Clerico A; Dominici C Oncotarget; 2016 Nov; 7(48):79342-79356. PubMed ID: 27764816 [TBL] [Abstract][Full Text] [Related]
16. Inhibition of the phosphodiesterase 4 (PDE4) enzyme reverses memory deficits produced by infusion of the MEK inhibitor U0126 into the CA1 subregion of the rat hippocampus. Zhang HT; Zhao Y; Huang Y; Dorairaj NR; Chandler LJ; O'Donnell JM Neuropsychopharmacology; 2004 Aug; 29(8):1432-9. PubMed ID: 15114341 [TBL] [Abstract][Full Text] [Related]
17. Radiosensitivity enhancement of human hepatocellular carcinoma cell line SMMC-7721 by sorafenib through the MEK/ERK signal pathway. Dai XF; Ding J; Zhang RG; Ren JH; Ma CM; Wu G Int J Radiat Biol; 2013 Sep; 89(9):724-31. PubMed ID: 23682582 [TBL] [Abstract][Full Text] [Related]
18. The effect of doxorubicin on MEK-ERK signaling predicts its efficacy in HCC. Choi J; Yip-Schneider M; Albertin F; Wiesenauer C; Wang Y; Schmidt CM J Surg Res; 2008 Dec; 150(2):219-26. PubMed ID: 18468633 [TBL] [Abstract][Full Text] [Related]
19. Synthetic lethal interaction between PI3K/Akt/mTOR and Ras/MEK/ERK pathway inhibition in rhabdomyosarcoma. Guenther MK; Graab U; Fulda S Cancer Lett; 2013 Sep; 337(2):200-9. PubMed ID: 23684925 [TBL] [Abstract][Full Text] [Related]
20. Significant anti-proliferation of human endometrial cancer cells by combined treatment with a selective COX-2 inhibitor NS398 and specific MEK inhibitor U0126. Gao J; Niwa K; Takemura M; Sun W; Onogi K; Wu Y; Seishima M; Mori H; Tamaya T Int J Oncol; 2005 Mar; 26(3):737-44. PubMed ID: 15703831 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]